Higher anti-drug antibody levels were associated with an increased risk for tumor necrosis factor inhibitor treatment failure in patients with noninfectious uveitis who received adalimumab, according to a study.
“Anti-drug antibodies (ADAs) can be a potential cause of treatment failure in patients treated with TNFi for noninfectious uveitis, and therapeutic drug monitoring may help exclude ADAs as a potential cause of treatment failure,” study authors Sunil Bellur, MD, and Shilpa Kodati, MD, told Healio/OSN.
The retrospective cross-sectional study included 54 patients with